5H+ of Networking
with other industry experts
WHY TO ATTEND
Comparability in Biosimilar Development
The structure of proteins
New developments in structure function relationship
In vitro pharmacology
Meet the expert trainers
Dr. Robert E. Zoubek
Senior Consultant at Granzer Regulatory Consulting & Services
Dr. Zoubek is passionate biochemist with large experience in the mitigation of protein aggregation and degradation, and the effective design of formulation studies - an experience which he combines wi
Dr. Carsten Brockmeyer, PhD
CEO at Formycon
Dr. Carsten Brockmeyer, PhD, is an independent expert and pioneer in the development of biopharmaceutical and biosimilar medicinal products. He has served from 1991 to 1998 as scientific group leader
Dipl. Chem. Martin Blüggel
Chief Executive Officer at Protagen Protein Services
Martin Blüggel is an expert for peptide and protein analysis, mass spectrometry and bioinformatics for protein analysis and proteomics. He is author of more than 35 scientific publications and has pr
Prof. Dr. Johannes Buchner
Chair at the Department of Chemistry at Technische Universitat Munchen
After attaining his PhD in biochemistry in 1991, the author worked at the National Institute of Health in Bethesda, USA. Since1998, he holds a chair at the department of chemistry at the Technische Un
Who should attend
This unique training covers a systematic evaluation and understanding of sustainable portfolio strategies, regulatory landscape, risk reduction and creating new market segments within generics and biosimilars industry.
One of our sales representatives will call you according to your preferences.
Thank you for your interest.
We appreciate your interest in this topic. The download should start automatically.
Your payment was successfull.
You should receive link to download your recording shortly.
Your friends have invites in their inbox.